MERCK & CO., INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 130.1 USD | -0.13% |
|
+2.00% | +19.30% |
| May. 09 | Merck Says Health Canada Approve Keytruda Combination in Biliary Tract Carcinoma | MT |
| May. 09 | Sector Update: Health Care Stocks Steady Pre-Bell Thursday | MT |
Presenter SpeechJaspreet Kaur Nandra (Attendees)Hello, and welcome to our virtual event, a pan...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
Pharmaceuticals
Calendar
2024-05-15
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
130.1
USD
Average target price
141.6
USD
Spread / Average Target
+8.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +19.30% | 329B | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B | |
| -2.71% | 159B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Transcript : Merck & Co., Inc. - Special Call